RESUMO
AIMS: Oral and/or oropharyngeal acute mucositis during and after chemo-radiotherapy (chemo-RT) for head and neck squamous cell carcinoma (HNSCC) can be extremely painful, sometimes requiring nasogastric feeding to enable adequate nutrition. The MASCC/ISOO evidence-based guidelines recommend benzydamine mouthwash for mucositis prevention in RT (recently updated to include chemo-RT), and a Cochrane systematic review found other agents to be effective in prophylaxis. Diclofenac mouthwash is licensed for painful oral mucosal inflammatory conditions but to our knowledge has not been assessed in chemo-RT-associated oral mucositis. METHOD: A clinical observation and service evaluation study in 10 patients undergoing chemo-RT for HNSCC to assess the potential value of diclofenac mouthwash (0.74 mg/mL) in reducing symptoms. Patients used 20ml of mouthwash up to 4 times a day starting in week 3 (of a 6-week course of treatment), recording pain and discomfort scores using a visual analogue scale on days 0, 1,7 and 14 (until the end of week 4). As per our current clinical practice, oral mucositis was not clinically scored as an outcome. Statistical analysis was performed using a one-way ANOVA. RESULTS: Using diclofenac mouthwash, 9/10 patients experienced pain score reduction from day 0 (mean score 6.75 ± SD 1.83) to day 2 (5.05 ± SD 1.62) and day 14 (4.09 ± SD 1.96). CONCLUSIONS: Diclofenac mouthwash may be beneficial for managing chemo-RT-induced oral mucositis. While a prospective randomised clinical trial is needed, it can be prescribed for this condition within its current licence.
Assuntos
Neoplasias de Cabeça e Pescoço , Lesões por Radiação , Estomatite , Quimiorradioterapia , Diclofenaco/uso terapêutico , Neoplasias de Cabeça e Pescoço/radioterapia , Humanos , Antissépticos Bucais/uso terapêutico , Dor/tratamento farmacológico , Estudos Prospectivos , Lesões por Radiação/tratamento farmacológico , Estomatite/tratamento farmacológico , Estomatite/etiologia , Estomatite/prevenção & controleRESUMO
UNLABELLED: The GDC recommend that early detection of oral cancer should form part of every dental surgeon's Continuing Professional Development. It is arguably the most serious condition that can arise within the oral cavity and regular screening practices may also help mitigate spurious claims of prior negligence for failure to detect the cancer at an early stage. Results for routine screening of the entire oral mucosa, together with risk status assessment, should be recorded in a patient's notes at every visit (both negative and positive findings). CLINICAL RELEVANCE: A knowledge of how to detect oral cancer early is an essential part of the dentist's armamentarium.